Weekly Recap: Q3 revenue tops $1 billion annualized run rate and AXS-12 FDA decision due May 1, 2027
Axsome Therapeutics (AXSM) reported strong third-quarter results, with revenue reaching a $1 billion annualized run rate and AUVELITY sales increasing by 53%. The FDA's decision on AXS-12 for narcolepsy-related cataplexy is anticipated by May 1, 2027, with pre-launch preparations underway. Despite a lowered price target from Morgan Stanley, the company holds $314 million in cash, though concerns about cash flow sustainability were noted.
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch
Axsome Therapeutics reported a significant surge in new prescriptions for its drug AUVELITY, particularly following its launch for Alzheimer's disease agitation. The company achieved $260 million in total net sales for the third quarter, with AUVELITY contributing $208 million, and has expanded its sales force to capitalize on this growth. Axsome also provided updates on its pipeline drugs, including SUNOSI and AXS-20.
Axsome at UBS Global Biopharma Conference 2026: growth buildout continues
Axsome Therapeutics presented at the UBS Global Biopharma Conference 2026, highlighting strong commercial momentum for AUVELITY, which achieved $208 million in Q3 2026 revenue and contributed to the company's first-ever annualized run rate above $1 billion. The company emphasized its expanded sales force and pipeline development, with significant growth expected in 2027 from both major depressive disorder and Alzheimer's disease agitation indications. Axsome maintained its long-term peak sales opportunity at $8 billion, split evenly between these two key indications.
Axsome Therapeutics (AXSM) Stock May Be Undervalued Following Strong Revenue Growth
Axsome Therapeutics (AXSM) has seen a significant stock gain of 295.8% over the past five years, prompting a closer look at its valuation relative to its sales, especially as it is still a loss-making company. Despite trading at a higher P/S ratio (8.6x) compared to the pharmaceuticals sector average (4.1x), its valuation is below its peer group (9.9x) and is considered undervalued when factoring in its growth profile and a recent revenue target exceeding US$1 billion. Analysts' consensus also suggests the stock is 48% undervalued, driven by its diverse CNS product portfolio and late-stage pipeline.
Morgan Stanley Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price
Morgan Stanley has lowered its price target for Axsome Therapeutics (NASDAQ:AXSM) from $249 to $223, while maintaining an "equal weight" rating, despite analyst consensus remaining a "Moderate Buy." Other firms have also adjusted their targets downward recently. The company recently reported better-than-expected quarterly revenue of $259.69 million and a loss of $0.25 per share, exceeding analyst estimates.
Morgan Stanley maintains Axsome Therapeutics at Equal-Weight, lowers price target to $223 from $249
Morgan Stanley has maintained its "Equal-Weight" rating on Axsome Therapeutics (AXSM) but reduced its price target from $249 to $223, a 10.4% decrease. This new target still implies a 54.5% upside from the stock's November 12 closing price of $144.37. Other analysts recently issued price targets for Axsome ranging from $239 to $273.
Is Axsome Therapeutics (AXSM) Undervalued As Revenue Run Rate Tops $1b?
Axsome Therapeutics (AXSM) has seen a rebound in its share price after reporting strong Q3 2026 results, with an annualized revenue run rate exceeding US$1 billion. Despite short-term gains, the stock is still down over a 90-day period, though its 5-year total shareholder return is significantly positive. Simply Wall St analysts believe Axsome is 45% undervalued, citing a pipeline of CNS products and an aggressive earnings ramp, while acknowledging risks like reliance on key products and ongoing net losses.
Axsome Therapeutics (AXSM) Stock May Be Reasonable On Strong Q3 Revenue Growth
Axsome Therapeutics (AXSM) has seen substantial share price growth over the past five years, despite a recent pullback. With strong Q3 revenue growth and an expanding neuroscience pipeline, the company's valuation against its sales is being scrutinized. Analysts and the Fair Ratio benchmark suggest that the current 7.9x Price/Sales (P/S) ratio, while above the sector average, may still reflect a discount given its growth prospects and recent financial updates.
UBS Adjusts Axsome Therapeutics Price Target to $239 From $256, Maintains Buy Rating
UBS has adjusted its price target for Axsome Therapeutics (AXSM) shares to $239 from $256, while reiterating a Buy rating on the stock. This revision follows recent updates regarding AXSM's Auvelity prescription trends and Q3 2026 results. The firm's analysis indicates that while Auvelity's launch trajectory is strong, competitive dynamics and long-term market share assumptions have led to a modest reduction in peak sales estimates.
UBS maintains Axsome Therapeutics at Buy, lowers price target to $239 from $256
UBS maintained its "Buy" rating for Axsome Therapeutics (AXSM) but lowered its price target to $239 from $256, representing a 6.6% decrease. This new price target implies a potential upside of 75.7% from the stock's closing price on November 2nd. Other analysts have recently issued price targets for Axsome Therapeutics ranging from $220 to $273.
Axsome Therapeutics Inc earnings beat by $0.33, revenue topped estimates
Axsome Therapeutics Inc reported a third-quarter EPS of $-0.25, surpassing analyst estimates by $0.33. The company's revenue also exceeded expectations, coming in at $259.7 million against a consensus estimate of $252.7 million. Despite the positive earnings, Axsome Therapeutics Inc's stock price has declined by 31.27% over the last three months, though it is up 6.39% over the past year.
Axsome Therapeutics reports Q3 EPS (25c), consensus (56c)
Axsome Therapeutics reported Q3 EPS of (25c), significantly beating the consensus of (56c), and revenue of $259.69M, surpassing the $249.93M consensus. The company achieved 52% year-over-year total revenue growth, exceeding a one-billion-dollar annual run rate, driven by demand for Auvelity and new patient initiations in Alzheimer’s disease agitation. Despite strong results, Axsome Therapeutics shares were down 12.7% in morning trading.
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Axsome Therapeutics (AXSM) reported a 52% year-over-year revenue growth in Q3, reaching $259.7 million, primarily driven by strong sales of AUVELITY for major depressive disorder and Alzheimer’s disease agitation. The company narrowed its net loss and expects sustained momentum for its commercial portfolio, along with several key pipeline milestones extending into 2027 for new drug candidates. Prescription growth across AUVELITY, SUNOSI, and SYMBRAVO contributed significantly to the positive financial results.
Axsome Therapeutics 3Q 2026: Revenue $259.7M, Net loss $12.9M, EPS $(0.25) — 10-Q Summary
Axsome Therapeutics reported its third-quarter 2026 results, showing a significant increase in revenue to $259.7 million, up 51.9% year-over-year. The company's net loss narrowed to $12.9 million, resulting in a diluted loss per share of $(0.25). Key business highlights include strong sales for AUVELITY, SUNOSI, and SYMBRAVO, as well as the FDA acceptance of the AXS-12 NDA for narcolepsy.
Axsome Q3 loss narrows expectations as revenue reaches $259.7m
Axsome Therapeutics reported a third-quarter 2026 net loss of $12.9 million, or $0.25 per share, which was better than analyst expectations of a $0.69 loss per share. The company's revenue reached $259.7 million, exceeding the average analyst estimate of $246.4 million. Despite a 21% decline in shares since the beginning of 2026, Axsome gained 7% over the past 12 months.
Axsome Therapeutics stock rises 2% on beat driven by strong product growth
Axsome Therapeutics Inc. (NASDAQ:AXSM) reported strong third-quarter results, surpassing analyst expectations with a 52% year-over-year revenue increase to $259.7 million and a narrower-than-expected loss per share of -$0.25. This performance, which led to a 2.13% rise in pre-market trading, was primarily fueled by robust sales growth from its products AUVELITY and SUNOSI. The company also provided updates on its clinical pipeline, including a Phase 3 trial initiation and an NDA target action date.
Axsome Therapeutics Shares Rise 2.13% as Q3 Revenue Jumps 52% and Loss Narrows
Axsome Therapeutics (NASDAQ:AXSM) shares rose 2.13% in pre-market trading after the company reported better-than-expected third-quarter 2026 financial results. Revenue surged 52% year-over-year to $259.7 million, driven by strong sales of AUVELITY and SUNOSI, while the loss per share narrowed significantly to $0.25. The company also provided updates on its clinical pipeline, including the initiation of a Phase 3 trial for AXS-05 and an upcoming regulatory decision for AXS-12.
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics announced strong financial results for the third quarter of 2026, with total net product revenue reaching $259.7 million, a 52% year-over-year increase. Key products like AUVELITY, SUNOSI, and SYMBRAVO all demonstrated significant sales growth, contributing to the company surpassing a one-billion-dollar annual run rate. Additionally, Axsome provided updates on its neuroscience pipeline, highlighting the initiation of the SUMMIT Phase 3 trial for AXS-05 for smoking cessation and anticipated milestones for several other drug candidates.
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics reported strong financial results for the third quarter of 2026, achieving $259.7 million in total net product revenue, a 52% year-over-year increase. This growth was driven by significant sales increases in AUVELITY, SUNOSI, and SYMBRAVO. The company also provided updates on its neuroscience pipeline, including the initiation of the SUMMIT Phase 3 trial for AXS-05 in smoking cessation and anticipated topline results for several other drug candidates in 2027.
Axsome Therapeutics (AXSM) Stock Still Looks Undervalued As Its 251% Run Continues
Axsome Therapeutics (AXSM) has seen a 251.2% stock return over the past 5 years, with its current price at US$143.45. Despite trading at a Price-to-Sales (P/S) ratio of 9.7x, which is double the industry average, Simply Wall St's analysis suggests the stock remains undervalued based on its growth expectations, margins, and risk profile. Analysts and community narratives also support an undervalued assessment, highlighting the company's expanding portfolio and sales potential.
Axsome Therapeutics, Inc (AXSM)
This article provides a snapshot of Axsome Therapeutics, Inc (AXSM) stock performance and key financial metrics. It details the current stock price, market capitalization, P/E ratio, revenue growth, and dividend yield. The report also highlights significant institutional holders like Renaissance Technologies, Citadel Advisors, and Bridgewater Associates, including their ownership percentages and recent activity.
Axsome Therapeutics (AXSM) Faces A Valuation Test Following Its CNS Growth Story
Axsome Therapeutics (AXSM) has experienced a significant pullback in its share price recently, despite strong longer-term returns and a growing CNS portfolio. The company is considered 49% undervalued by many analysts, with a fair value estimate of $282.51, which hinges on the successful scaling of its central nervous system portfolio. However, its current P/S ratio of 9.7x is above the industry average, suggesting that expectations may already be elevated.
Axsome Therapeutics stock may move 8.6% on earnings report
Axsome Therapeutics Inc. (NASDAQ:AXSM) stock is projected to move 8.6% based on options data ahead of its earnings report on November 2. Historically, the stock's actual movement has often exceeded the implied options move in five out of the past eight earnings announcements. Investors will be watching closely to see if this trend continues with the upcoming report.
Axsome Therapeutics stock may move 8.6% on earnings report By Investing.com
Axsome Therapeutics Inc. (NASDAQ:AXSM) stock is projected to move 8.6% when its earnings report is released on November 2, according to options data compiled by Bloomberg. The stock's actual movement has often exceeded options-implied forecasts in previous earnings announcements. The company's upcoming earnings report is scheduled before the market opens on November 2.
Washington Trust Advisors Inc. Buys 43,788 Shares of Axsome Therapeutics, Inc. $AXSM
Washington Trust Advisors Inc. significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by over 25,000% during the third quarter, now holding 43,963 shares valued at approximately $8.1 million. This comes as Axsome shares have fallen to $145.04, below their moving averages, and the company reported a quarterly loss and revenue miss. Despite insider selling by the CEO and COO totaling around $12.6 million, analysts maintain a "Moderate Buy" consensus with an average price target of $275.74.
Axsome Therapeutics, Inc. Estimates – NASDAQ:AXSM
This page on TradingView provides financial estimates and actuals for Axsome Therapeutics, Inc. (NASDAQ:AXSM). Users can explore reported financial data and analyst estimates for income statements, balance sheets, cash flow, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The information is available on both annual and quarterly bases.
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
Axsome Therapeutics is expected to report strong third-quarter 2026 results, driven by the continued uptake of its lead drug, Auvelity, for major depressive disorder and its recent approval for Alzheimer's disease agitation. The company's other drugs, Sunosi and Symbravo, also contribute significantly to its revenue. However, Axsome faces increasing competition in the highly competitive central nervous system (CNS) market.
Assenagon Asset Management S.A. Sells 203,877 Shares of Axsome Therapeutics, Inc. $AXSM
Assenagon Asset Management S.A. significantly reduced its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by selling 203,877 shares in the third quarter, retaining 250,805 shares valued at $46.2 million. This comes as Axsome Therapeutics reported a quarterly loss of $0.99 per share and revenue of $218.4 million, both missing analyst estimates. Despite mixed financial results and insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $275.74.
Axsome Therapeutics (AXSM) Stock May Trade At A Discount To Growth
Axsome Therapeutics (AXSM) has seen a significant 296.3% gain over the past five years, but its current valuation suggests it might be trading at a discount. Despite trading at a P/S ratio of 10.9x, which is higher than the industry average, Simply Wall St's analysis and community narratives suggest the stock could be undervalued by as much as 43% when considering its growth potential, profitability, and risk profile. Investors are encouraged to examine analyst forecasts for future performance before making investment decisions.
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $295
RBC Capital has reiterated its Buy rating for Axsome Therapeutics (AXSM.US) and maintained its target price of $295. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $268
Needham has reiterated its Buy rating for Axsome Therapeutics (AXSM.US) and maintained its price target of $268. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com
RBC Capital has reiterated its Outperform rating for Axsome Therapeutics (NASDAQ:AXSM) with a $295.00 price target, despite a recent 28% stock decline attributed to lower-than-expected prescription trends. The firm believes the stock is fundamentally dislocated from its fair value and is currently undervalued, with an RSI suggesting oversold territory. RBC Capital maintains a positive outlook, citing a $2.3 billion opportunity in Alzheimer’s disease agitation by 2035 and expectations for beatable lower quarterly expectations.
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 4.4% - Here's Why
Axsome Therapeutics (NASDAQ:AXSM) shares increased by 4.4% on Wednesday, despite a significant drop in trading volume. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $275.74, and institutional investors own 81.49% of its shares. However, the company missed recent quarterly EPS and revenue estimates, and insiders have sold approximately $12.6 million worth of stock in the last 90 days.
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform
RBC Capital has reiterated an Outperform rating for Axsome Therapeutics (NASDAQ:AXSM) with a $295 price target, despite a recent 28% stock decline attributed to lower-than-expected prescription trends. The firm believes the stock is fundamentally undervalued, trading significantly below its pre-Alzheimer’s disease agitation approval levels, and sees a $2.3 billion opportunity in Alzheimer’s disease agitation by 2035. RBC Capital anticipates beatable lower expectations for the upcoming quarter, aligning with other analysts who also hold positive outlooks and increased price targets for Axsome.
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com
RBC Capital has reiterated an Outperform rating for Axsome Therapeutics (NASDAQ:AXSM) with a $295 price target, despite a recent 28% stock decline attributed to lower-than-expected prescription trends. The firm believes the stock is fundamentally undervalued, trading significantly lower than its pre-approval price for Alzheimer's disease agitation treatment. RBC Capital projects a $2.3 billion opportunity in Alzheimer’s disease agitation by 2035 and anticipates the company will surpass expectations in the upcoming quarter.
Axsome Therapeutics Inc (AXSM) Earnings, Actual EPS, EPS Estimates & Results
This article provides details on Axsome Therapeutics Inc (AXSM) upcoming and historical earnings data. It outlines the estimated EPS and revenue for Q3 '26, as well as past quarterly results, including whether the company beat or missed analyst estimates. The information presented includes estimated and reported EPS, revenue, and the surprise percentage.
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – DUS:19X
This article provides the enterprise value to EBIT forward for Axsome Therapeutics, Inc. (DUS:19X). It is presented as part of the financial data available on TradingView, which aggregates market and reference data from various sources. The data itself indicates no trades for the specified period.
Axsome Therapeutics Stock: 12 Straight Red Days, Down 15%
Axsome Therapeutics (AXSM) stock has experienced 12 consecutive trading days of decline, resulting in a 15.3% cumulative drop and a $1.6 billion reduction in market value. This downturn contrasts with the S&P 500's gain during the same period, suggesting a stock-specific slide. The company's fundamentals show strong revenue growth but a negative operating margin, raising concerns for investors.
Tangible book value per share of Axsome Therapeutics, Inc. – HAN:19X
This article displays the tangible book value per share for Axsome Therapeutics, Inc. (HAN:19X) on the TradingView platform. The content primarily shows the financial data point and related navigation and copyright information for the TradingView website.
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Axsome Therapeutics (AXSM) with a $276 price target. This follows a similar Buy rating from RBC Capital, although Morgan Stanley reiterated a Hold rating. Axsome Therapeutics reported a quarterly revenue of $218.38 million and a GAAP net loss of $51.31 million for the quarter ending June 30.
Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss
Axsome Therapeutics (AXSM) stock has experienced an 11-day losing streak, resulting in a 14.1% decline and erasing approximately $1.4 billion from its market value. This underperformance is not attributed to the broader market, as the S&P 500 gained 1.4% during the same period. While the company shows strong revenue growth, its operating margin is negative, suggesting fundamental challenges despite its stock performance over the past year.
Is Axsome Therapeutics (AXSM) A Bargain After Setting Its November 2 Earnings Date?
Axsome Therapeutics (AXSM) has scheduled its Q3 2026 earnings release for November 2, 2026. Despite recent short-term volatility with its share price down over the last 30 and 90 days, the company shows strong longer-term momentum with significant 1-year and 5-year returns. Simply Wall St's analysis suggests Axsome is currently 40% undervalued, with a fair value of $282.51, driven by its growing CNS portfolio and late-stage clinical programs.
10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13%
Axsome Therapeutics (AXSM) stock has experienced a 10-day losing streak, falling 13.2% and reducing its market value by $1.3 billion. This decline significantly underperformed the S&P 500, which gained 0.8% over the same period. Despite revenue growth, the company's operating loss raises concerns for potential investors, suggesting a need for careful consideration beyond just the stock price.
Is Axsome Therapeutics (AXSM) A Bargain After Setting Its November 2 Earnings Date?
Axsome Therapeutics (AXSM) is preparing for its Q3 earnings release on November 2, 2026, amid recent stock volatility but strong long-term returns. Despite being considered 40% undervalued with a fair value of $282.51 due to its CNS portfolio, the company faces risks if key products underperform or net losses strain cash. Investors are advised to look beyond headlines and analyze the company's data and risks.
Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018 -- Data Talk
Axsome Therapeutics is currently on track for its longest losing streak since December 2018. This data point highlights a significant negative trend in the company's stock performance.
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $295.00 by Analysts at Royal Bank Of Canada
Royal Bank of Canada has reduced its price target for Axsome Therapeutics (NASDAQ:AXSM) to $295.00 from $297.00, while maintaining an "outperform" rating, indicating a potential 74% upside. This comes after Axsome Therapeutics missed analysts' consensus estimates for both EPS and revenue in its latest quarterly report. Despite the price target cut and recent insider selling totaling $12.6 million, the stock still holds a consensus "Moderate Buy" rating from analysts with an average target of $275.74.
Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days
Axsome Therapeutics (AXSM) stock has experienced a 9-day losing streak, dropping 11.8% and erasing approximately $1.2 billion from its market value. While the S&P 500 gained 1.3% during the same period, Axsome's fundamentals show strong revenue growth (56.9%) but an operating loss, which might be contributing to the selling pressure. The article suggests that such a slide prompts a review of beaten-down stocks whose fundamentals remain strong.
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Axsome Therapeutics (NASDAQ: AXSM) announced it will report its third quarter 2026 financial results on Monday, November 2, 2026, before the U.S. financial markets open. Following the release, Axsome management will host a conference call at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Investors can access the live webcast or a replay on the company's website.
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Axsome Therapeutics, Inc. announced it will report its third-quarter 2026 financial results on Monday, November 2, 2026, before the opening of U.S. financial markets. The company will also host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. A live webcast and replay of the call will be available on the company's website.
Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call.
Axsome Therapeutics (AXSM) is scheduled to report its third-quarter 2026 financial results on November 2, 2026, before the U.S. financial markets open. Following the release, the company's management will host a conference call at 8:00 a.m. Eastern Time to discuss the results and provide a business update. A live webcast and replay of the call will be available on Axsome's website.